Essjay Solutions Newsletter – January 2026

January 2026 opens the year with a strong focus on cardiometabolic disease, immunology, oncology, and obesity, alongside notable momentum in regulatory approvals, pricing reform, and manufacturing investment. The month highlights accelerating innovation in GLP-1–based therapies, expanding access through oral and higher-dose formulations, and a continued reshaping of global pharma economics through landmark US pricing agreements.

From pharmacovigilance signals and expanded vaccine indications to breakthrough autoimmune therapies and major public–private investment commitments, January reflects a life sciences sector balancing scientific ambition with affordability, access, and long-term sustainability.

Regulatory and Pharmacovigilance Updates

PRAC and EU Safety Referrals

No new urgent EU safety referral procedures were initiated in January. One ongoing Article 31 referral for levamisole hydrochloride, triggered by Romania, remains under review, with no procedures finalised this month.

New Safety Signals Identified

Signals emerging from EU spontaneous reporting systems include:

• Atropine eye drops (paediatric myopia): Strabismus

• Darolutamide: Angioedema

• Oxacillin: DRESS syndrome

• Vortioxetine: Acute pancreatitis

• Zolbetuximab: Protein-losing gastroenteropathy

• Zuranolone: Suicidal ideation

• Multiple X-ray contrast agents: Fixed drug eruption

Signal Follow-up Ongoing

• Cefazolin (± lidocaine): Kounis syndrome

• Erdafitinib: Accelerated growth

• Pegylated liposomal doxorubicin: Renal-limited thrombotic microangiopathy

• Pemetrexed: Lupus erythematosus

These updates reinforce continued vigilance around oncology, neurology, and diagnostic agents as their clinical use broadens.

Regulatory Approvals and Authorisations

Vaccines, Metabolic Disease, and Respiratory Care

• GSK – Arexvy: European Commission approval expanded RSV vaccination to adults aged 18+, significantly widening protection beyond older and high-risk groups.

• Novo Nordisk – Wegovy (oral semaglutide): FDA approval of the first oral GLP-1 receptor agonist for weight management, delivering weight loss comparable to injectable formulations.

• Novo Nordisk – Wegovy 7.2 mg injection: UK MHRA approval of a higher-dose option for patients not achieving goals on standard dosing.

• GSK – Nucala: MHRA approval for uncontrolled COPD, marking an expansion of biologics into broader respiratory populations.

Neurology and Autoimmune Disease

• Eisai & Biogen – Leqembi (SC autoinjector): FDA Priority Review for a subcutaneous formulation enabling at-home dosing for early Alzheimer’s disease.

• Novartis – ianalumab: FDA Breakthrough Therapy designation for Sjögren’s disease, addressing a major unmet need in autoimmune care.

Research and Clinical Developments

Oncology

January delivered multiple late-stage oncology readouts supporting new standards of care:

• Gilead – Trodelvy + Keytruda: Phase 3 data show a 35% reduction in progression risk in first-line metastatic triple-negative breast cancer.

• Moderna & Merck: Five-year follow-up confirms durable benefit of personalised mRNA cancer vaccine combinations in high-risk melanoma.

• Pfizer – Braftovi combination: Improved response durability in BRAF V600E–mutated metastatic colorectal cancer.

• Johnson & Johnson – Rybrevant combinations: Encouraging activity in difficult-to-treat colorectal cancer populations.

Immunology and Dermatology

• Sanofi – amlitelimab: Positive phase 2 data in moderate-to-severe atopic dermatitis with favourable safety and flexible dosing.

• Takeda – zasocitinib: Phase 3 trials demonstrate rapid and sustained skin clearance in plaque psoriasis, supporting TYK2 inhibition as a competitive oral strategy.

• AstraZeneca – Saphnelo (SC): Phase 3 results confirm efficacy and convenience gains in systemic lupus erythematosus.

Obesity, Metabolism, and Cell Therapy

• Genentech – CT-388: Phase 2 obesity data show substantial weight loss and metabolic normalisation.

• AstraZeneca & CSPC: Strategic collaboration to expand weight-management pipelines using AI-driven peptide discovery.

• Novo Nordisk & Aspect Biosystems: Expanded partnership advancing off-the-shelf cellular therapies for diabetes.

Healthcare Policy, Pricing, and Access

January underscored a structural shift in US pharmaceutical economics, with multiple large-cap companies reaching agreements aligned with federal drug-pricing priorities:

• AbbVie, Amgen, BMS, Merck, Novartis, and Gilead all announced multi-year deals involving price reductions, expanded direct-to-patient access, Medicaid support, and tariff relief.

• These agreements are paired with massive reinvestment commitments, collectively exceeding hundreds of billions of dollars in US R&D, manufacturing, and infrastructure.

Together, they signal a new equilibrium between affordability, domestic production, and long-term innovation incentives.

Industry, Marketing, and Investment

• Medical Affairs Evolution: Thought leadership highlights the growing need for creative, data-driven engagement to combat HCP burnout and misinformation.

• AstraZeneca: Announced a $15bn investment in Chinese R&D and manufacturing by 2030, strengthening global cell therapy and radioconjugate capabilities.

• Novo Nordisk Foundation: €736m commitment to Denmark’s BioInnovation Institute to accelerate European life sciences competitiveness.

• Vibrant Therapeutics: $61m financing round to advance logic-gated T-cell engager oncology programmes.

Overall Themes

Metabolic Momentum: Obesity and cardiometabolic disease dominate approvals, pipelines, and partnerships.
Convenience as Value: Oral formulations, higher-dose flexibility, and at-home administration increasingly define competitive advantage.
Oncology Durability: Long-term follow-up data reinforce the importance of sustained survival benefit, not just early endpoints.
Affordability Meets Investment: Pricing reform is increasingly paired with large-scale manufacturing and R&D commitments rather than retrenchment.
Regulatory Sophistication: Breakthrough designations, priority reviews, and expanded indications highlight regulators’ role in accelerating access.

Essjay Summary

January 2026 illustrates a life sciences sector recalibrating for scale, access, and durability. Breakthrough therapies in obesity, autoimmune disease, and oncology are matched by structural shifts in pricing, manufacturing, and regulatory strategy. As innovation accelerates, success increasingly depends on delivering not just scientific advances, but convenient, affordable, and globally scalable solutions that align patient outcomes with health system sustainability.